Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transcriptomics

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Transcriptomics. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-004961-14 Sponsor Protocol Number: UV2013/4 Start Date*: 2014-06-11
    Sponsor Name:Kliniken Kärnan Urology Centre
    Full Title: Pilot study to investigate the mode of action (MoA) of Uro-Vaxom® on a molecular level in pre-menopausal women suffering from recurrent urinary tract infections (rUTI)
    Medical condition: Recurrent urinary tract infections (rUTI)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10038140 Recurrent urinary tract infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003041-35 Sponsor Protocol Number: TJB2224 Start Date*: 2022-10-20
    Sponsor Name:CHU de Liège
    Full Title: Impact of the immune system on response to inactivated influenza vaccine (IIV) in allogeneic stem cell recipients
    Medical condition: Allogeneic hematopoietic stem cell recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004355-33 Sponsor Protocol Number: MH002-UC-201 Start Date*: 2021-09-23
    Sponsor Name:MRM Health NV
    Full Title: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Mechanistic Effects, and Effects on Disease Activity of MH002 in Subjects with Mild to Moderate Ulcerative Colitis: A First-in...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001856-51 Sponsor Protocol Number: 12.007 Start Date*: 2014-08-26
    Sponsor Name:Aleksander Krag
    Full Title: Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial
    Medical condition: Liver fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10016648 Fibrosis liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-004016-26 Sponsor Protocol Number: Clin_COVID-19_Corok Start Date*: 2021-10-18
    Sponsor Name:Meilahti Vaccine Research Center - Helsinki University Hospital
    Full Title: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection"
    Medical condition: None
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001339-33 Sponsor Protocol Number: SCITVITD3 Start Date*: 2018-07-05
    Sponsor Name:Academisch medisch centrum Amsterdam
    Full Title: A randomized, double-blind, placebo-controlled, study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with moderate to severe allergic rhinitis/ ...
    Medical condition: subcutaneous immunotherapy in allergic rhinitis (AR) patients with allergies to birchpollen
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001806-40 Sponsor Protocol Number: STATLiver2019 Start Date*: 2019-09-03
    Sponsor Name:Afsnit 360, Gastroenheden
    Full Title: Statins for prevention of disease progression and hospitalization in Liver Cirrhosis: A multi-center, randomized, double blind, placebo-controlled trial. The STATLiver Trial.
    Medical condition: Cirrhosis of the liver
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002069-21 Sponsor Protocol Number: D5180C00013 Start Date*: 2018-10-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled C...
    Medical condition: Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000476-26 Sponsor Protocol Number: N14DAR Start Date*: 2020-07-13
    Sponsor Name:Netherlands Cancer Institute
    Full Title: Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA)
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036912 Prostate cancer stage 0 PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036917 Prostate cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036919 Prostate cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036918 Prostate cancer stage II PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003413-26 Sponsor Protocol Number: MINDEP Start Date*: 2015-12-14
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: Understanding the molecular basis for the use of adjunctive anti-inflammatory treatment in treatment resistant depression: a stratified, randomised, placebo-controlled, experimental medicine study ...
    Medical condition: Depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001474-29 Sponsor Protocol Number: SAINT Start Date*: 2020-05-07
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-001309-22 Sponsor Protocol Number: 2593957 Start Date*: 2021-03-29
    Sponsor Name:IQVIA Commercial GmbH & Co. OHG
    Full Title: Evaluation of immunological effects of the hedgehog inhibitors on basal cell carcinoma - An open label, prospective, observational biomarker study of the DeCOG.
    Medical condition: Basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064679 Basal cell carcinoma of skin in situ LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003309-88 Sponsor Protocol Number: ROR-PH-302 Start Date*: 2020-06-02
    Sponsor Name:United Therapeutics Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World He...
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002062-39 Sponsor Protocol Number: CAIN457M2302 Start Date*: 2019-01-17
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) SK (Completed) CZ (Completed) BE (Completed) DK (Completed) LT (Completed) GR (Completed) NL (Completed) ES (Completed) HU (Completed) PL (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003204-13 Sponsor Protocol Number: 74527 Start Date*: 2021-11-15
    Sponsor Name:Radboudumc
    Full Title: Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia
    Medical condition: Candidemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002712-51 Sponsor Protocol Number: 2020 Start Date*: 2021-03-05
    Sponsor Name:Kirsi Pietiläinen
    Full Title: Semaglutide as an adjunct to dieting in the treatment of type 2 diabetes – effects on glucose metabolism, prevention of weight regain and peripheral tissue metabolic activation
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002063-26 Sponsor Protocol Number: CAIN457M2301 Start Date*: 2019-01-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) PT (Completed) HU (Completed) SK (Completed) CZ (Completed) BE (Completed) GR (Completed) AT (Completed) SE (Completed) ES (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-005032-14 Sponsor Protocol Number: MOT-C-201 Start Date*: 2017-04-27
    Sponsor Name:INOTREM S.A.
    Full Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients with Septic Shock. A Randomised, Double-blind, Two-stage, Placebo Controlled Study.
    Medical condition: Septic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003050-24 Sponsor Protocol Number: B7931022 Start Date*: 2019-08-02
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR T...
    Medical condition: Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) HU (Completed) BG (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004827-22 Sponsor Protocol Number: BM41-VD3 Start Date*: 2017-07-25
    Sponsor Name:Academic Medical Center
    Full Title: A randomized, double-blind, placebo-controlled, double-dummy study to determine the safety/tolerability of a simultaneous subcutaneous treatment of BM41 and vitamin D 3 in patients with moderate to...
    Medical condition: moderate to severe allergic rhinitis/rhino-conjunctivitis caused by birch pollen (with or without concomitant mild to moderate persistent asthma)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:17:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA